Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Pat. 2014 Oct;24(10):1053-65. doi: 10.1517/13543776.2014.947961. Epub 2014 Aug 9.

Galectin-3 inhibitors: a patent review (2008-present).

Author information

1
Griffith University, Institute for Glycomics , Gold Coast Campus, Queensland 4222 , Australia +617 555 27023 ; +617 555 28098 ; h.blanchard@griffith.edu.au.

Abstract

INTRODUCTION:

Galectin-3 (Gal-3), a lectin with preference for β-galactoside-containing carbohydrates, is a structurally unique member of the galectin family. It is ubiquitously expressed in various mammalian tissues with a wide distribution from the intracellular environment to the extracellular space. Gal-3 is a well-established player in numerous diseases, from infections to heart failure. Notably, as Gal-3 overexpression is associated with cancer drug resistance, it has been identified as a valuable therapeutic target in the fight against cancers.

AREAS COVERED:

This review discusses the recent progress of patent applications (2008-present) and the current knowledge of pertinent Gal-3-inhibitor interactions in an effort to progress the development of selective and high affinity carbohydrate-based inhibitors targeting Gal-3, with an emphasis on engaging a structure-based drug design rationale.

EXPERT OPINION:

The lack of commercially available anti-Gal-3 therapeutic reagents and its clear involvement in serious disease, notably cancer, leads to an urgent need for development of inhibitors that specifically target Gal-3. Design of potent and selective carbohydrate inhibitors targeting Gal-3 is challenging due to relative weak protein-carbohydrate interactions along with the high sequence homology in the carbohydrate binding site region among galectins. To date, some chemical scaffolds have been exploited for design of promising effective Gal-3 inhibitors for cancer therapy.

KEYWORDS:

carbohydrate; galectin; inhibitor design; patents

PMID:
25109359
DOI:
10.1517/13543776.2014.947961
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center